Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 159-168

  Kim, S J ^a   Im, Y H ^a   Markowitz, S D ^b   Bang, Y J ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

DNA methylation; Receptors; TGF ; Transcriptional regulation; Tumor suppressor

Indexed keywords

PROTEIN SERINE THREONINE KINASE; SMAD PROTEIN; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL; CANCER INHIBITION; CARCINOGENESIS; ENZYME INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; GENE SILENCING; HUMANS; MUTATION; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0034027480     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00039-8     Document Type: Review

References (102)

1. Roberts A.B., Sporn M.B. The transforming growth factor-βs. Robert A.B., Sporn M.B., Peptide growth factors and their receptors. Handbook of experimental pharmacology. 1990;419-472 Springer-Verlag, Heidelberg.
2. Kim D.H., Kim S.-J. Transforming growth factor-β receptors: role in physiology and disease. J. Biomed. Sci. 3:1996;143-158.
3. Markowitz S., Roberts A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine & growth factor reviews. vol. 7:1996;93-102 Elsevier Science, Cambridge.
4. Massaguë J. TGF-β signal transduction. Annu. Rev. Biochem. 67:1998;753-791.
5. Reiss M. Transforming growth factor-β and cancer: a love-hate relationship? Oncol. Res. 9:1997;447-457.
6. Park K., Kim S.-J., Bang Y.-J., et al. Genetic changes in the transforming growth factor-β (TGF-β) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-β Proc. Natl. Acad. Sci. USA. 91:1994;8772-8776.
7. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
8. Myeroff L.L., Parsons R., Kim S.-J., et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55:1995;5545-5547.
9. Garrigue-Antar L., Muñoz-Antonia T., Gesmonde J., Vellucci V.F., Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 55:1995;3892-3987.
10. Yang H.-K., Kang S.H., Kim Y.-S., Won K., Bang Y.-J., Kim S.-J. Truncation of the TGF-β receptor gene results in insensitivity to TGF-β in human gastric cancer cells. Oncogene. 18:1999;2213-2219.
11. Hahm K.-B., Cho K., Lee C., et al. The EWS-FLI1 oncogene of Ewing sarcoma represses TGF-β type II receptor gene expression. Nat. Genet. 23:1999;222-227.
12. Sporn M.B., Roberts A.B. Peptide growth factors are multifunctional. Nature. 332:1988;217-219.
13. Sun L., Wu G., Willson J.K.V., et al. Expression of transforming growth factor type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:1994;26449-26455.
14. Chang J., Park K., Bang Y.-J., Kim W.S., Kim D., Kim S.-J. Expression of transforming growth factor-β type II receptor reduced tumorigenicity in human gastric cancer cells. Cancer Res. 57:1997;2856-2859.
15. Guo R.J., Wang Y., Kaneko E., et al. Analyses of mutation and loss of heterozygosity of coding sequences of the entire transforming growth factor β type II receptor gene in sporadic human gastric cancer. Carcinogenesis. 19:1998;1539-1544.
16. Tani M., Takenoshita S., Kohno T., et al. Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. Carcinogenesis. 18:1997;1119-1121.
17. Kang S.H., Won K., Chung H.W., et al. Genetic integrity of transforming growth factor β (TGF-β) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF-β Int. J. Cancer. 77:1998;620-625.
18. Chu T.Y., Lai J.S., Shen C.Y., Liu H.S., Chao C.F. Frequent aberration of the transforming growth factor-β receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix. Int. J. Cancer. 80:1999;506-510.
19. Aaltonen L., Peltomäki P., Leach F., et al. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1993;812-816.
20. Fishel R., Lescoe M., Rao M., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
21. Lonov Y., Peinado M., Malkhosyan S., Shibata D., Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 363:1993;558-561.
22. Leach F., Nicolaides N., Papadopulos N., et al. Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer. Cell. 75:1993;1215-1225.
23. Thibodeau S., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:1993;816-819.
24. Liu B., Nicolaides N., Markowitz S., et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 9:1995;48-53.
25. Eshleman J., Markowitz S. Microsatellite instability in inherited and sporadic neoplasms. Curr. Opin. Oncol. 7:1995;83-89.
26. Parsons R., Myeroff L.L., Liu B.L., et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
27. Lu S.L., Akiyama Y., Nagasaki H., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-β type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 216:1995;452-457.
28. Lu S.L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56:1996;4595-4598.
29. Akiyama Y., Yagi O.K., Ishikawa T., Nagasaki H., Saitoh K., Yuasa Y. Genetic alterations are frequent in APC but rare in the TGF-β type II receptor gene in cancer in adenomas of the colon. Cancer Lett. 125:1998;89-96.
30. Grady W.M., Myeroff L.L., Swinler S.E., et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancer. Cancer Res. 59:1999;320-324.
31. Grady W.M., Rajput A., Myeroff L.L., et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58:1998;3101-3104.
32. Samowitz W.S., Slattery M.L. Transforming growth factor-β receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am. J. Pathol. 151:1997;33-35.
33. Akiyama Y., Iwanaga R., Saitoh K. Transforming growth factor β type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology. 112:1997;33-39.
34. Chung Y.J., Song J.M., Lee J.Y., et al. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. Cancer Res. 56:1996;4662-4665.
35. Ohue M., Tomita N., Monden T., et al. Mutations of the transforming growth factor β type II receptor gene and microsatellite instability in gastric cancer. Int. J. Cancer. 68:1996;203-206.
36. Oliveira C., Seruca R., Seixas M., Sobrinho-Simoes M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different 'target genes': a study of the TGF-β RII, IGFII R, BAX genes. Am. J. Pathol. 153:1998;1211-1219.
37. Shinmura K., Tani M., Isogaki J., Wang Y., Sugimura H., Yokota J. RER phenotype and its associated mutations in familial gastric cancer. Carcinogenesis. 19:1998;247-251.
38. Wu M.S., Lee C.W., Shun C.T. Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res. 58:1998;1494-1497.
39. Chung Y.J., Kim K.M., Choi J.R., Choi S.W., Rhyu M.G. Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability. Int. J. Cancer. 82:1999;782-788.
40. Shitara Y., Yokozaki H., Yasui W., Takenoshita S., Nagamachi Y., Tahara E. Mutation of the transforming growth factor-β type II receptor gene is a rare event in human sporadic gastric carcinoma. Int. J. Oncol. 12:1998;1061-1065.
41. Izumoto S., Arita N., Ohnishi T., et al. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett. 112:1997;251-256.
42. Nagai M., Kawarada Y., Watanabe M., et al. Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors. AntiCancer Res. 19:1999;1765-1768.
43. Togo G., Toda N., Kanai F., et al. A transforming growth factor beta type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res. 56:1996;5620-5623.
44. Salvucci M., Lemoine A., Saffroy R., et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene. 18:1999;181-187.
45. Vincent F., Hagiwara K., Ke Y., Stoner G.D., Demetrick D.J., Bennett W.P. Mutation analysis of the transforming growth factor β type II receptor in sporadic human cancers of the pancreas, liver and breast. Biochem. Biophys. Res. Commun. 223:1996;561-564.
46. Kawate S., Takenoshita S., Ohwada S., et al. Mutation analysis of transforming growth factor β type II receptor, Smad2, Smad4 in hepatocellular carcinoma. Int. J. Oncol. 14:1999;127-131.
47. Furuta K., Misao S., Takahashi K., et al. Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma. Int. J. Cancer. 81:1999;851-853.
48. Takenoshita S., Mogi A., Tani M., et al. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-β type II receptor gene in sporadic human breast cancer. Oncol. Rep. 5:1998;367-371.
49. Tomita S., Deguchi S., Miyaguni T., Muto Y., Tamamoto T., Toda T. Analyses of microsatellite instability and the transforming growth factor-β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res. Treat. 53:1999;33-39.
50. D'Abronzo F.H., Swearingen B., Klibanski A., Alexander J.M. Mutational analysis of activin/transforming growth factor-β type I and type II receptor kinase in human pituitary tumors. J. Clin. Endocrinol. Metab. 84:1999;1716-1721.
51. De M., Yan W., de Jonge R.R., Garrigue-Antar L., Vellucci V.F., Reiss M. Functional characterization of transforming growth factor β type II receptor mutants in human cancer. Cancer Res. 58:1998;1986-1992.
52. Yasumi K., Guo R.J., Hanai H., et al. Transforming growth factor β type II receptor (TGF-β RII) mutation in gastric lymphoma without mutator phenotype. Pathol. Int. 48:1998;134-137.
53. Lynch M.A., Nakashima R., Song H., et al. Mutational analysis of the transforming growth factor β receptor type II gene in human ovarian carcinoma. Cancer Res. 58:1998;4227-4232.
54. Knaus P.I., Lindemann D., DeCoteau J.F. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol. Cell Biol. 16:1996;3480-3489.
55. Munoz-Antonia T., Li X., Reiss M., Jackson R., Antonia S. A mutation in the transforming growth factor β type II receptor gene promoter associated with loss of gene expression. Cancer Res. 56:1996;4831-4835.
56. Hougaard S., Norgaard P., Abrahamsen N., Moses H.L., Spang-Thomsen M., Skovgaard Poulsen H. Inactivation of the transforming growth factor β type II receptor in human small cell lung cancer cell lines. Br. J. Cancer. 79:1999;1005-1011.
57. Lu S.L., Kawabata M., Imamura T. HNPCC associated with germline mutation in the TGF-β type II receptor gene. Nat. Genet. 19:1998;17-18.
58. Lu S.L., Kawabata M., Imamura T., Miyazono K., Yuasa Y. Two divergent signaling pathways for TGF-β separated by a mutation of its type II receptor gene. Biochem. Biophys. Res. Commun. 259:1999;385-390.
59. Kimchi A., Wang X.-F., Weinberg R., Cheifetz S., Massaguë J. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science. 240:1988;196-199.
60. Horie K., Yamashita H., Mogi A., Takenoshita S., Miyazono K. Lack of transforming growth factor-β type II receptor expression in human retinoblastoma cells. J. Cell Physiol. 175:1998;305-313.
61. Kadin M., Cavaille-Coll M.W., Gertz R., Massaguë J., Cheifetz S., George D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA. 91:1994;6002-6006.
62. Kaneko H., Horiike S., Taniwaki M., Misawa S. Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-β receptor type II gene mutation. Leukemia. 10:1996;1696-1699.
63. Molenaar J.J., Gerard B., Chambon-Pautas C., et al. Microsatellite instability and frameshift mutations in BAX and transforming growth factor-β RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood. 92:1998;230-233.
64. Rooke H.M., Vitas M.R., Crosier P.S., Crosier K.E. The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia. 13:1999;535-541.
65. de Jonge R.R., Garrigue-Antar L., Vellucci V.F., Reiss M. Frequent inactivation of the transforming growth factor β type II receptor in small-cell carcinoma cells. Oncol. Res. 9:1997;89-98.
66. Caligo M.A., Ghimenti C., Marchetti A., et al. Microsatellite alterations and p53, TGFβ RII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer. Int. J. Cancer. 78:1998;606-609.
67. Missero C., Filvaroff E., Dotto G.P. Induction of transforming growth factor-β1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc. Natl. Acad. Sci. USA. 88:1991;3489-3493.
68. Kim D.H., Chang J.H., Lee K.H., Lee H.-Y., Kim S.-J. Mechanism of E1A-induced transforming growth factor-β1 (TGF-β1) resistance in mouse keratinocytes involves repression of TGF-β1 type II receptor transcription. J. Biol. Chem. 272:1997;688-694.
69. Okamoto A., Jiang W., Kim S.-J., et al. Overexpression of human cyclin D1 reduces the transforming growth factor β (TGF-β) type II receptor and growth inhibition by TGF-β1 in an immortalized human esophageal epithelial cell line. Proc. Natl. Acad. Sci. USA. 91:1994;11576-11580.
70. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature. 321:1986;209-213.
71. Jones P.A. DNA methylation errors and cancer. Cancer Res. 56:1996;2463-2467.
72. Ammanamanchi S., Kim S.-J., Sun L.Z., Brattain M.G. Induction of transforming growth factor-β receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine. J. Biol. Chem. 273:1998;16527-16534.
73. Bae H.W., Geiser A.G., Kim D.H., et al. Characterization of the promoter region of the human transforming growth factor-β type II receptor gene. J. Biol. Chem. 270:1995;29460-29468.
74. Choi S.-G., Yi Y., Kim Y.-S., et al. A novel ets-related transcription factor, ERTESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor gene. J. Biol. Chem. 273:1998;110-117.
75. Chang C.-H., Scott G.H., Kuo W.-L., et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene. 14:1997;1617-1622.
76. Oettgen P., Alani R.M., Barcinski M.A., et al. Isolation and characterization of a novel epithelial specific transcription factor, ESE-1, a member of the ets family. Mol. Cell Biol. 17:1997;4419-4433.
77. Tymms M.J., Ng A.Y.N., Thomas R.S., et al. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene. 15:1997;2449-2462.
78. Andreoli J.M., Jang S.-I., Chung E., Coticchia C.M., Steinert P.M., Markova N.G. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res. 25:1997;4287-4295.
79. Macleod K., Leprince D., Stehelin D., et al. The ets gene family. Trends Biochem. Sci. 17:1992;251-256.
80. Lai Z.-C., Rubin G.M. Negative control of photoreceptor development in Drosophila by the product of the yan gene, an ETS domain protein. Cell. 70:1992;609-620.
81. Sgouras D.N., Athanasiou M.A., Beal G.J. Jr, et al. ERF: and ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. EMBO J. 14:1995;4781-4793.
82. Delattre O., Zucman J., Ploustagel B., et al. Gene fusion with an ETS DNA binding domain caused by chromosome translocation in human cancers. Nature. 359:1992;162-165.
83. Sorensen P.H.B., Lessnick S.L., Lopez-Terrada D., et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 6:1994;146-151.
84. Jeon I.-S., Davis J.N., Braun B.S., et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 10:1995;1229-1234.
85. May W., Gishizky M.L., Lessnick S.L., et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. USA. 90:1993;5752-5756.
86. May W.A., Arvand A., Thompson A.D., Braun B.S., Wright M., Denny C.T. EWS/FLI-1 induced manic fringe renders NIH-3T3 cells tumorigenic. Nat. Genet. 17:1997;495-497.
87. Klemsz M.J., Maki R.A., Papayannopoulou T., Moore J., Hromas R. Characterization of the ets oncogene family member, fli-1. J. Biol. Chem. 268:1993;5769-5773.
88. Kim I.Y., Ahn H.-J., Zelner D.J. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 56:1996;44-48.
89. Chen T., Carter D., Garrigue-Antar L., Reiss M., et al. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. 58:1998;4805-4810.
90. Anbazhagan R., Bornman D.M., Johnston J.C., Westra W.H., Gabrielson E. The S387Y mutations of the transforming growth factor-β receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma et al. Cancer Res. 59:1999;3363-3364.
91. DeCoteau J.F., Knaus P.I., Yankelev H., et al. Loss of functional cell surface transforming growth factor β (TGF-β) type I receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:1997;5877-5881.
92. Chen T., de Vries E.G., Hollema H., et al. Structural alterations of transforming growth factor-β receptor genes in human cervical carcinoma. Int. J. Cancer. 82:1999;43-51.
93. Pasche B., Luo Y., Rao P.H., et al. Type I transforming growth factor β receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res. 58:1998;2727-2732.
94. Wang J., Han W., Zborowska E., et al. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J. Biol. Chem. 271:1996;17366-17371.
95. Wagner M., Kleeff J., Lopez M.E., Bockman I., Massaque J., Korc M. Transfection of the type I TGF-β receptor restores TGF-beta responsiveness in pancreatic cancer. Int. J. Cancer. 78:1998;255-260.
96. Kang SH, Bang Y-J, Im Y-H et al. Transcriptional repression of the transforming growth factor-β type I receptor by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 1999;18:7280-86
97. Issa J.-P.J., Ottaviano Y.L., Celano P., et al. Methylation of the oestrogen receptor CpG island links aging and neoplasia in human colon. Nat. Genet. 7:1994;536-540.
98. Merlo A., Herman J.G., Mao L., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
99. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700-9704.
100. Sakai T., Toguchida J., Ohtani N., et al. Allele specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Human Genet. 48:1991;880-888.
101. Yoshiura K., Kanai Y., Ochiai A., et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. USA. 92:1995;7416-7419.
102. Bloom B.B., Humphries D.E., Kuang P.P., Fine A., Goldstein R.H. Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-β receptor: regulation by TGF-β Biochim. Biophys. Acta. 1312:1996;243-248.